Who We Are
Titan Pharmaceuticals develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. ProNeura implants enhance patient care by providing non-fluctuating, stable levels of medication in the blood for up to one year, potentially offering health and safety advantages over other routes of administration and improving medical outcomes.
Titan's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. Probuphine has the potential to increase patient compliance and decrease the risk of diversion.
Titan is in the early stages of product development programs utilizing ProNeura for the treatment of Parkinson's disease and hypothyroidism. It's also evaluating the feasibility of additional product candidates that would be suitable for the treatment of several chronic diseases, including certain hormonal deficiencies, type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia and others. In addition to developing its pipeline internally, Titan is exploring joint development projects and opportunities for licensing its ProNeura technology to other companies, both in the U.S. and globally.